Description
+ Include: 5 videos + 5 file sub vtt + 1 pdf, size: 50.77 GB
+ Target Audience: rheumatologists, geneticists & immunologists
+ Sample video: contact me for sample video
+ Information:
IGAS 2023: THE GENETIC FRONTIER OF SPONDYLOARTHRITIS
“From GWAS to Function: Decoding the Ankylosing Spondylitis Genome”
🗓️ Conference Dates: March 30 – April 1, 2023
📍 Location: Naples, Italy (Centro Congressi Federico II)
Academic Host: The International Genetics of Ankylosing Spondylitis (IGAS) Consortium
ℹ️ General Information
Welcome to the premier gathering of the global Spondyloarthritis (SpA) research community. The IGAS 2023 Conference represents a critical turning point in rheumatology: the shift from simply identifying risk genes to understanding their function in the immune system.
Held in the historic academic center of Naples, this exclusive summit brings together the world’s leading geneticists and immunologists. Unlike general rheumatology meetings, IGAS focuses entirely on the molecular engine driving Axial Spondyloarthritis. This course offers a deep dive into how the “Dark Matter” of the genome interacts with the microbiome to trigger inflammation.
-
Format: High-Level Scientific Plenary + Interactive “Young Investigator” Sessions.
-
Focus: Translational Medicine (Genetics, Pathogenesis, New Therapies).
-
Language: English.
👥 Target Audience
This advanced curriculum is designed for medical professionals and researchers operating at the cutting edge of immunology:
-
Academic Rheumatologists: Who need to understand the “Polygenic Risk Scores” that will soon guide prognosis in clinical practice.
-
Geneticists & Immunologists: Investigating the functional consequences of HLA-B27 and ERAP1 interaction.
-
Pharma & Biotech Researchers: Looking for the next generation of therapeutic targets beyond TNF and IL-17 inhibitors.
🎯 Learning Objectives
By analyzing the 2023 consortium data, participants will be able to:
-
Interpret Polygenic Risk Scores (PRS): Understand how cumulative genetic risk is calculated and its potential to predict disease severity in axSpA.
-
Connect Gut & Spine: Explain the causal relationship between the gut microbiome and entheseal immunity using Mendelian Randomization techniques.
-
Target the Misfolding: Evaluate the role of ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) and its potential as a drug target.
-
Analyze Rare Variants: Differentiate between common GWAS hits and rare, high-impact variants found in multi-case families.
📚 Conference Topics & Modules
*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the below
DAY 1 – 30th March 2023
| 8:30 – 8:45
8.30 – 9:00 |
Registration CME
Welcome |
| 9:00 – 9:20 | Overview on genetic in axSpA | Matthew Brown |
| 9:20 – 9:40 | Polygenic risk score in biomedical research | Richard Oram |
| 9:40 – 10:00 | Polygenic risk scores in axSpA | Huji Xu |
| 10:00 – 10:20 | Functional evaluation of ERAP1 in axSpA | Tony Kenna |
| 10:20 – 10:40 | Questions and Discussion (Regarding the subject included in the session) | interactive |
from 10:40 to 11:00
| 11:00 – 11:20 | Exploring rare variants in multicase Families | Felicie Costantino |
| 11:20 – 11:40 | News from B27 transgenic drosophila | Vincent Rincheval |
| 11:40 – 12:00 | Functional genomics in axSpA | Matteo Vecellio |
| 12:00 – 12:15 | Questions and Discussion (Regarding the subject included in the session) | Interactive |
| 12:15 – 12:25 | Validating the arthritogenic hypothesis: connections between gut and entheseal immunity | Jose Garrido Mesa |
| 12:25 – 12:35 | Identifying causal relationships between gut microbiome and axSpA through mendelian randomization | Nicholas Harvey |
| 12:35 – 12:45 | Exploring TLR signaling in DC from HLA-B27 transgenic rat | Ait Ali Said Amel |
| 12:45 – 1:00 | Discussion (Regarding the subject included in the session) |
from 1:00 PM to 2:00 PM
| 2.00 – 2:20 | Microbiome and axSpA pathogenesis | Maxime Breban |
| 2:20 – 2:40 | The role of gut bacteria in the development of Spondyloarthritis | Anne Sophie Bergot |
| 2:40 – 3:00 | Fecal microbial transplantation in axSpA | Maja Kragsnæs |
| 3:00 – 3:20 | Questions and Discussion (Regarding the subject included in the session) | Interactive |
From 3:20 PM to 3:40 PM
| 3:40 – 4:00 | Gut and axSpA: evidence and controversies | Francesco Ciccia |
| 4.00 – 4:20 | News from the gut in axSpA | Thomas Bazin |
| 4:20 – 4:40 | Modulation of epithelial intestinal barrier in the pathogenesis of inflammatory arthritis | Aline Bozec |
| 4:40 -5:00 | New mucosal player in axSpA pathogenesis | Daniele Mauro |
| 5:00 – 5:20 | Questions and Discussion (Regarding the subject included in the session)
|
Interactive |
DAY 2 – 31st March 2023
| 8.50 – 09:10 | Co-receptors in helper and cytotoxic T cells function | Ondrej Stepanek |
| 09:10 – 09:30 | DCs and Th17 interaction in B27 transgenic rat | Simon Glatigny |
| 09:30 – 09:50 | Single cell insights into the immunology of axSpA | Davide Simone |
| 09:50 – 10:10 | Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides | Paul Bowness |
| 10:10 – 10:30 | Questions and Discussion (Regarding the subject included in the session) | interactive |
From 10:30 AM to 10:50 AM
| 10:50 – 11:10 | TCR immunology | Jia Jia Lim |
| 11:10 – 11:30 | Interleukin 17 inhibitors and the effect on enthesitis and pain in Spondyloarthritis | Marije Koenders |
| 11.30 – 11.50 | Immunopathogenesis of enthesistis in axSpA | Dennis Mc Gonagle |
| 11.50 – 12.10 | Questions and Discussion (Regarding the subject included in the session) |
from 12:10 PM to 1:30 PM
| 1:30 – 1:50 | MIF: a potential therapeutic target in axSpA | Nigil Haroon |
| 1:50 – 2:10 | Dysregulated CTL Exhaustion in axSpA | Michael Tang |
| 2:10 – 2:30 | ZRANB1 in AS pathogenesis | Archita Shrinath |
| 2:30 – 3:00 | Questions and Discussion (Regarding the subject included in the session) | Interactive |
From 3:00 PM to 3:20 PM
| 3:20 – 3:40 | Immune tolerance and resolution of inflammation in inflammatory arthritis | Stefano Alivernini |
| 3:40 – 4:00 | Metabolic control of Innate lymphoid cells | Chen Dong |
| 4:00 – 4:20 | Questions and Discussion (Regarding the subject included in the session) | Interactive |
| 4:20 – 4:30 | Profiling T cell receptor polymorphisms in axSpA | Zoya Qaiyum |
| 4:30 – 4:40 | Leaky gut in SpA: focus on ZEB proteins | Chiara Rizzo |
| 4:40 – 4:50 | How does TGFb affect CD4+ T cell response in axSpA? | Marc Lauraine |
|
4:50 – 5:05 |
Discussion (Regarding the subject included in the session) |
| 5:05 – 5:25 | The lecture has not been included in the educational program CME
From patient side: the role of Ixekizumab in patient reported outcomes |
Ennio Favalli |
| 5:25 – 5:45 | The lecture has not been included in the educational program CME
The recognition and management of early PsA: which role for the IL23 inhibitor GuselKumab?
|
Ilenia Pantano |
DAY 3 – 1st April 2023
| 8:30 – 8:50 | Immune-stromal interaction in bone formation | Nicole Horwood |
| 8:50 – 9:10 | Mechano-inflammation in axSpA | Dirk Elewaut |
| 9:10 – 9:30 | Fibroblast Activation Protein (FAP) PET-CT for depicting osteoproliferation in axSpA patient | Andreas Ramming |
| 9:30 – 9:50 | Questions and Discussion (Regarding the subject included in the session) | interactive |
| 9:50 – 10:10 | Sex-specific differences in axSpA: myth or truth? | Irene Van der Host-Bruinsma |
| 10:10 – 10:30 | Sex differences in treatment efficacy of interleukin 17 inhibitors in Spondyloarthritis | Emmerik Leijten |
| 10:30 – 10:50 | Insight in PsA by imaging | AGeorg Schett |
| 10:50 – 11:00 | Questions and Discussion (Regarding the subject included in the session) | interactive |
| 11:10 – 11:30 | Biomarkers predictive of clinical response in AxSpA | John Reveille |
| 11:30 – 11:50 | ASAS-Eular recommendations for the management of AxSpA | Lianne Gensler |
| 11.50 – 1 2.10 | The added value of sonography in SpA diagnosis and monitoring | Maria Antonietta D’Agostino |
| 12:10 – 12.30 | Questions and Discussion (Regarding the subject included in the session) | Interactive |
| 12:30 – 12:40 | Comorbidities and metabolic burdern in early PSA: data from prospective metapsa cohort | Alla Ishchenko |
| 12:40 – 12:50 | Cytof profiling of blood populations in axSpA” | Claudia Worth |
| 12:50 – 1:00 | IL-24 as biomarkers in axSpA | Giulio Forte |
| 1:00 – 1:15 | Discussion (Regarding the subject included in the session) |
| 1:15- 1:25 | “Mark Asquith” award for best young presentation |
Reviews
There are no reviews yet.